Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections Inspira announced its bio-electronic ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Unlike oral gabapentin and lidocaine patches, the Company believes that the biphasic delivery mechanism of GTx-101 has the potential ... clinical benefits to decrease symptoms associated with Ataxia ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

but the mechanisms involved vary between different conditions, necessitating distinct therapeutic approaches Friedreich ataxia (FRDA) is caused by deficiency of a mitochondrial protein ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...

The clinical mechanism of true BM development is hematogenic spread. Autopsy series overestimate the incidence of BMs. Two old and large studies found an incidence of 0.63–0.7%. A recent study ...